CIK: 0001704132 · Show all filings
Period: Q2 2024 (← Previous) (Next →)
Filing Date: Aug 13, 2024
Total Value ($000): $148,850 (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| PHVS | Pharvaris N.V. | 4,293,854 | $80,724 | 54.2% | $27.50 | -26.0% | COM | N69605108 |
| KURA | Kura Oncology, Inc. | 1,849,947 | $38,090 | 25.6% | $20.39 | +0.8% | COM | 50127T109 |
| SNDX | Syndax Pharmaceuticals, Inc. | 875,000 | $17,964 | 12.1% | $22.62 | -7.5% | COM | 87164F105 |
| — | Lyell Immunopharma, Inc. | 8,325,000 | $12,071 | 8.1% | $16.24 | — | COM | 55083R104 |